WeightLoss+

Science

The evidence behind every protocol.

We say what's proven, what's promising, and what's uncertain. Below: the trials, reviews, and mechanistic papers behind the medications we prescribe.

Our evidence standard.

For FDA-approved medications, we rely on phase-3 randomized trials and post-market evidence. For compounded preparations, we anchor to the active-ingredient evidence and clearly mark what's known vs. what's extrapolated. For peptides, we cite the available human data and acknowledge where it's preclinical only.

Library

Selected citations.

GLP-1

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine · 2021

68-week RCT: mean weight change of −14.9% with 2.4 mg semaglutide vs −2.4% with placebo. Established the modern GLP-1 standard for obesity care.

GLP-1

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine · 2022

72-week RCT: mean weight reduction of −20.9% at the 15 mg dose. Demonstrated additive benefit of dual GLP-1/GIP receptor agonism.

GLP-1

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · New England Journal of Medicine · 2023

Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight/obesity without diabetes.

Peptide

BPC-157 and Tendon Healing: Preclinical Evidence Review

Sikiric P, Seiwerth S, Rucman R, et al. · Current Pharmaceutical Design · 2018

Comprehensive review of BPC-157 mechanisms across tendon, ligament, and gut models. Human evidence remains limited; we set expectations accordingly.

Peptide

Sermorelin: A Review of Clinical Use in Growth-Hormone Deficiency

Walker RF. · Clinical Interventions in Aging · 2006

Foundational review of sermorelin's mechanism as a growth-hormone-releasing-hormone analog and clinical use in adult GH support.

Sexual Wellness

Bremelanotide (PT-141) for Hypoactive Sexual Desire Disorder

Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019

Pivotal RECONNECT trials demonstrating bremelanotide efficacy and tolerability in premenopausal women with HSDD.

Longevity

NAD+ Metabolism and Healthy Aging

Covarrubias AJ, Perrone R, Grozio A, Verdin E. · Nature Reviews Molecular Cell Biology · 2021

Mechanistic review of NAD+ in mitochondrial function and aging biology. Sets a careful frame for clinical NAD+ supplementation expectations.

Longevity

Glutathione: Antioxidant Properties and Clinical Implications

Pizzorno J. · Integrative Medicine (Encinitas) · 2014

Clinical review of glutathione physiology, depletion patterns, and supplementation considerations.

Questions about a specific study?

Your clinician can walk you through what the data means for your specific situation.

Talk to a clinician
Call Melanie(512) 555-1212